Patient biodistribution of intraperitoneally administered Yttrium-90-labeled antibody

D. J. Hnatowich, M. Chinol, D. A. Siebecker, M. Gionet, T. Griffin, P. W. Doherty, R. Hunter, K. R. Kase

Research output: Contribution to journalArticle

Abstract

Although 90Y is one of the best radionuclides for radioimmunotherapeutic applications, the lack of gamma rays in its decay complicate the estimation of radiation dose since its biodistribution cannot be accurately determined by external imaging. A limited clinical trial has been conducted with tracer doses (1 mCi) of 90Y in five patients who then received second-look surgery such that tissue samples were obtained for accurate radioactivity quantitation by in vitro counting. The anti-ovarian antibody OC-125 as the F(ab')2 fragment was coupled with diethylenetriaminepentaacetic acid, radiolabeled with 90Y and administered intraperitoneally to patients with suspected or documented ovarian cancer. Size exclusion and ion exchange high performance liquid chormatography analysis of patient ascitic fluid and serum samples showed no evidence of radiolabeled instability although a high molecular weight species (presumably immune complex) was observed in three patients. Total urinary excretion of radioactivity prior to surgery averaged 7% of the administered radioactivity while at surgery the mean organ accumulation was 8% of the administered radioactivity in serum, 10% in liver, 7% in bone marrow, and 19% in bone with large patient to patient variation. The mean tumor/normal tissue radioactivity ratio varied between 3 and 25. On the assumption that the above radioactivity levels were achieved immediately following administration, that the radioactivity remained in situ until decayed and that the dimensions of tumor were sufficient to completely attenuate the emissions of 90Y, the dose to tumor for a 1-mCi administration would be ~50 rad with normal tissues receiving ~8 rad.

Original languageEnglish
Pages (from-to)1428-1434
Number of pages7
JournalJournal of Nuclear Medicine
Volume29
Issue number8
Publication statusPublished - 1988

Fingerprint

Yttrium
Radioactivity
Antibodies
Second-Look Surgery
Neoplasms
Ascitic Fluid
Ion Exchange
Gamma Rays
Antigen-Antibody Complex
Serum
Radioisotopes
Ovarian Neoplasms
Anti-Idiotypic Antibodies
Molecular Weight
Bone Marrow
Clinical Trials
Radiation
Bone and Bones
Acids
Liver

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Hnatowich, D. J., Chinol, M., Siebecker, D. A., Gionet, M., Griffin, T., Doherty, P. W., ... Kase, K. R. (1988). Patient biodistribution of intraperitoneally administered Yttrium-90-labeled antibody. Journal of Nuclear Medicine, 29(8), 1428-1434.

Patient biodistribution of intraperitoneally administered Yttrium-90-labeled antibody. / Hnatowich, D. J.; Chinol, M.; Siebecker, D. A.; Gionet, M.; Griffin, T.; Doherty, P. W.; Hunter, R.; Kase, K. R.

In: Journal of Nuclear Medicine, Vol. 29, No. 8, 1988, p. 1428-1434.

Research output: Contribution to journalArticle

Hnatowich, DJ, Chinol, M, Siebecker, DA, Gionet, M, Griffin, T, Doherty, PW, Hunter, R & Kase, KR 1988, 'Patient biodistribution of intraperitoneally administered Yttrium-90-labeled antibody', Journal of Nuclear Medicine, vol. 29, no. 8, pp. 1428-1434.
Hnatowich DJ, Chinol M, Siebecker DA, Gionet M, Griffin T, Doherty PW et al. Patient biodistribution of intraperitoneally administered Yttrium-90-labeled antibody. Journal of Nuclear Medicine. 1988;29(8):1428-1434.
Hnatowich, D. J. ; Chinol, M. ; Siebecker, D. A. ; Gionet, M. ; Griffin, T. ; Doherty, P. W. ; Hunter, R. ; Kase, K. R. / Patient biodistribution of intraperitoneally administered Yttrium-90-labeled antibody. In: Journal of Nuclear Medicine. 1988 ; Vol. 29, No. 8. pp. 1428-1434.
@article{86ee65633c06492b8b7f026c86460b56,
title = "Patient biodistribution of intraperitoneally administered Yttrium-90-labeled antibody",
abstract = "Although 90Y is one of the best radionuclides for radioimmunotherapeutic applications, the lack of gamma rays in its decay complicate the estimation of radiation dose since its biodistribution cannot be accurately determined by external imaging. A limited clinical trial has been conducted with tracer doses (1 mCi) of 90Y in five patients who then received second-look surgery such that tissue samples were obtained for accurate radioactivity quantitation by in vitro counting. The anti-ovarian antibody OC-125 as the F(ab')2 fragment was coupled with diethylenetriaminepentaacetic acid, radiolabeled with 90Y and administered intraperitoneally to patients with suspected or documented ovarian cancer. Size exclusion and ion exchange high performance liquid chormatography analysis of patient ascitic fluid and serum samples showed no evidence of radiolabeled instability although a high molecular weight species (presumably immune complex) was observed in three patients. Total urinary excretion of radioactivity prior to surgery averaged 7{\%} of the administered radioactivity while at surgery the mean organ accumulation was 8{\%} of the administered radioactivity in serum, 10{\%} in liver, 7{\%} in bone marrow, and 19{\%} in bone with large patient to patient variation. The mean tumor/normal tissue radioactivity ratio varied between 3 and 25. On the assumption that the above radioactivity levels were achieved immediately following administration, that the radioactivity remained in situ until decayed and that the dimensions of tumor were sufficient to completely attenuate the emissions of 90Y, the dose to tumor for a 1-mCi administration would be ~50 rad with normal tissues receiving ~8 rad.",
author = "Hnatowich, {D. J.} and M. Chinol and Siebecker, {D. A.} and M. Gionet and T. Griffin and Doherty, {P. W.} and R. Hunter and Kase, {K. R.}",
year = "1988",
language = "English",
volume = "29",
pages = "1428--1434",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "8",

}

TY - JOUR

T1 - Patient biodistribution of intraperitoneally administered Yttrium-90-labeled antibody

AU - Hnatowich, D. J.

AU - Chinol, M.

AU - Siebecker, D. A.

AU - Gionet, M.

AU - Griffin, T.

AU - Doherty, P. W.

AU - Hunter, R.

AU - Kase, K. R.

PY - 1988

Y1 - 1988

N2 - Although 90Y is one of the best radionuclides for radioimmunotherapeutic applications, the lack of gamma rays in its decay complicate the estimation of radiation dose since its biodistribution cannot be accurately determined by external imaging. A limited clinical trial has been conducted with tracer doses (1 mCi) of 90Y in five patients who then received second-look surgery such that tissue samples were obtained for accurate radioactivity quantitation by in vitro counting. The anti-ovarian antibody OC-125 as the F(ab')2 fragment was coupled with diethylenetriaminepentaacetic acid, radiolabeled with 90Y and administered intraperitoneally to patients with suspected or documented ovarian cancer. Size exclusion and ion exchange high performance liquid chormatography analysis of patient ascitic fluid and serum samples showed no evidence of radiolabeled instability although a high molecular weight species (presumably immune complex) was observed in three patients. Total urinary excretion of radioactivity prior to surgery averaged 7% of the administered radioactivity while at surgery the mean organ accumulation was 8% of the administered radioactivity in serum, 10% in liver, 7% in bone marrow, and 19% in bone with large patient to patient variation. The mean tumor/normal tissue radioactivity ratio varied between 3 and 25. On the assumption that the above radioactivity levels were achieved immediately following administration, that the radioactivity remained in situ until decayed and that the dimensions of tumor were sufficient to completely attenuate the emissions of 90Y, the dose to tumor for a 1-mCi administration would be ~50 rad with normal tissues receiving ~8 rad.

AB - Although 90Y is one of the best radionuclides for radioimmunotherapeutic applications, the lack of gamma rays in its decay complicate the estimation of radiation dose since its biodistribution cannot be accurately determined by external imaging. A limited clinical trial has been conducted with tracer doses (1 mCi) of 90Y in five patients who then received second-look surgery such that tissue samples were obtained for accurate radioactivity quantitation by in vitro counting. The anti-ovarian antibody OC-125 as the F(ab')2 fragment was coupled with diethylenetriaminepentaacetic acid, radiolabeled with 90Y and administered intraperitoneally to patients with suspected or documented ovarian cancer. Size exclusion and ion exchange high performance liquid chormatography analysis of patient ascitic fluid and serum samples showed no evidence of radiolabeled instability although a high molecular weight species (presumably immune complex) was observed in three patients. Total urinary excretion of radioactivity prior to surgery averaged 7% of the administered radioactivity while at surgery the mean organ accumulation was 8% of the administered radioactivity in serum, 10% in liver, 7% in bone marrow, and 19% in bone with large patient to patient variation. The mean tumor/normal tissue radioactivity ratio varied between 3 and 25. On the assumption that the above radioactivity levels were achieved immediately following administration, that the radioactivity remained in situ until decayed and that the dimensions of tumor were sufficient to completely attenuate the emissions of 90Y, the dose to tumor for a 1-mCi administration would be ~50 rad with normal tissues receiving ~8 rad.

UR - http://www.scopus.com/inward/record.url?scp=0023784131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023784131&partnerID=8YFLogxK

M3 - Article

C2 - 3404257

AN - SCOPUS:0023784131

VL - 29

SP - 1428

EP - 1434

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 8

ER -